Registered number
09999335
LIQMEDS LIFECARE LIMITED
Filleted Accounts
31 March 2024
LIQMEDS LIFECARE LIMITED
Registered number: 09999335
Balance Sheet
as at 31 March 2024
Notes 2024 2023
£ £
Fixed assets
Investments 4 50 50
Current assets
Debtors 5 673,877 1,299,251
Cash at bank and in hand 6,294 6,816
680,171 1,306,067
Creditors: amounts falling due within one year 6 (303,354) (19,983)
Net current assets 376,817 1,286,084
Net assets 376,867 1,286,134
Capital and reserves
Called up share capital 100 100
Profit and loss account 376,767 1,286,034
Shareholders' funds 376,867 1,286,134
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Dr Amrut Naik
Director
Approved by the board on 19 February 2025
LIQMEDS LIFECARE LIMITED
Notes to the Accounts
for the period from 7 November 2023 to 31 March 2024
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Changes in the accounting reference dates
During the year, the company changed its accounting reference date from 6 Novemeber to 31 March. As a result, the current financial statements cover a 5-month period from 7 November 2023 to 31 March 2024. The comparative figures cover a 10-month period from 1 January 2023 to 6 November 2023.
Going concern
The financial statements have been prepared on a going concern basis. The directors have assessed the company’s financial position and performance and have concluded that there are no material uncertainties that may cast significant doubt on the company’s ability to continue as a going concern for the foreseeable future. Accordingly, the directors believe that the going concern basis of accounting is appropriate.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Research and development
Research and development expenditure is written off to the profit and loss account in the year in which it is incurred.
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
2 Audit information
The audit report is unqualified.
Senior statutory auditor: Devender Arora ACA
Firm: The Corporate Practice Limited
Date of audit report: 19 February 2025
3 Employees 2024 2023
Number Number
Average number of persons employed by the company 0 0
4 Investments
Investments in
subsidiary
undertakings
£
Cost
At 7 November 2023 50
At 31 March 2024 50
There was no movement in fixed assets investments during the period.
Above investments comprise of investments in the below listed entity:
Company Country Share class % of capital
Oncosol Limited England Ordinary 50
5 Debtors 2024 2023
£ £
Trade debtors 14,318 14,441
Amounts owed by group undertakings and undertakings in which the company has a participating interest 115,470 -
Deferred tax asset 303,089 -
Other debtors 241,000 1,284,810
673,877 1,299,251
6 Creditors: amounts falling due within one year 2024 2023
£ £
Trade creditors 5,640 5,640
Amounts owed to group undertakings and undertakings in which the company has a participating interest 279,522 -
Taxation and social security costs 7,863 7,863
Other creditors 10,329 6,480
303,354 19,983
7 Events after the reporting date
The directors confirm that there have been no significant events occurring after the balance sheet date that would require adjustment or disclosure in the financial statements.
8 Related party transactions
In accordance with Financial Reporting Standard 102 (FRS 102), the company has disclosed all related party transactions. Transactions with wholly-owned group members have been exempted from disclosure as permitted by paragraph 33.1A of FRS 102.
9 Controlling party
Zydus Pharmaceuticals UK Limited is the controlling party.
10 Other information
LIQMEDS LIFECARE LIMITED is a private company limited by shares and incorporated in England. Its registered office is:
Sandretto Building
Cavalry Hill Industrial Park
Weedon
Northampton
NN7 4PP
LIQMEDS LIFECARE LIMITED 09999335 false 2023-11-07 2024-03-31 2024-03-31 VT Final Accounts April 2024 Dr Amrut Naik No description of principal activity 09999335 2023-01-01 2023-11-06 09999335 core:WithinOneYear 2023-11-06 09999335 core:ShareCapital 2023-11-06 09999335 core:RetainedEarningsAccumulatedLosses 2023-11-06 09999335 2023-11-07 2024-03-31 09999335 bus:PrivateLimitedCompanyLtd 2023-11-07 2024-03-31 09999335 bus:Audited 2023-11-07 2024-03-31 09999335 bus:Director40 2023-11-07 2024-03-31 09999335 1 2023-11-07 2024-03-31 09999335 2 2023-11-07 2024-03-31 09999335 1 2023-11-07 2024-03-31 09999335 countries:England 2023-11-07 2024-03-31 09999335 bus:FRS102 2023-11-07 2024-03-31 09999335 bus:FilletedAccounts 2023-11-07 2024-03-31 09999335 bus:SmallCompaniesRegimeForAccounts 2023-11-07 2024-03-31 09999335 2024-03-31 09999335 core:WithinOneYear 2024-03-31 09999335 core:ShareCapital 2024-03-31 09999335 core:RetainedEarningsAccumulatedLosses 2024-03-31 09999335 2023-11-06 iso4217:GBP xbrli:pure